Related Experiment Video
Updated: May 15, 2026
09:31
Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
Published on: November 5, 2016
Development of modified release gliclazide biological macromolecules using natural biodegradable polymers
Vipulkumar D Prajapati1, Krupa H Mashru, Himanshu K Solanki
1Department of Pharmaceutics, SSR College of Pharmacy, Saily-Silvassa Road, Saily, Silvassa, UT of DNH 396230, India. vippra2000@yahoo.com
International Journal of Biological Macromolecules
|January 12, 2013
Summary
Researchers developed modified release beads of gliclazide using sodium alginate with pectin or gellan gum. Optimal formulations showed biphasic drug release, offering a promising approach for sustained gliclazide delivery.
Area of Science:
- Pharmaceutical Technology
- Drug Delivery Systems
- Materials Science
Background:
- Modified release dosage forms are crucial for improving patient compliance and therapeutic efficacy.
- Gliclazide is an oral hypoglycemic agent requiring controlled release for optimal glycemic control.
- Sodium alginate, gellan gum, and pectin are biocompatible polymers suitable for developing drug delivery systems.
Purpose of the Study:
- To formulate and characterize modified release gliclazide beads using sodium alginate combined with gellan gum or pectin.
- To evaluate the influence of polymer ratios on bead properties and drug release kinetics.
- To compare the in vitro performance of optimized formulations with commercial gliclazide tablets.
Main Methods:
- Gliclazide beads were prepared using the ionotropic gelation method with varying ratios of sodium alginate and gellan gum or pectin.
- Physicochemical parameters including swelling, entrapment efficiency, and morphology were evaluated.
- In vitro drug release studies were conducted over 12 hours.
- Drug release kinetics were analyzed using Higuchi and Korsmeyer-Peppas models.
Main Results:
- Increased polymer concentration led to higher swelling and entrapment efficiency but posed production challenges due to viscosity.
- Optimized formulations (sodium alginate:pectin 2:1 and sodium alginate:gellan gum 6:0.75) exhibited spherical morphology.
- These optimized beads demonstrated a biphasic in vitro release profile with an initial burst release followed by sustained release up to 12 hours.
- Release kinetics followed matrix diffusion (Higuchi model) and Korsmeyer-Peppas models.
Conclusions:
- Sodium alginate combined with pectin or gellan gum is effective for developing modified release gliclazide beads.
- The optimized formulations provide a biphasic drug release pattern suitable for sustained glycemic control.
- These novel beads represent a viable alternative to conventional modified release gliclazide tablets.
Related Concept Videos
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:23Modified-Release Drug Delivery Systems: Classification
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
01:30Modified-Release Drug Delivery Systems: Bioavailability
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...